The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline

      This paper is only available as a PDF. To read, Please Download here.
      The dexamethasone suppression test (DST) was conducted in 95 elderly DSM-III-R depressed patients randomized for treatment with moclobemide (MOC; 400 mg daily), nortriptyline (NT; 75 mg daily), or placebo (PBO) in a 7-week double-blind multicenter study. Patients were assessed weekly using various clinical scales, including the 17-item Hamilton Depression Rating Scale. The DST was administered at baseline and at the end of treatment. At baseline, no relationship was found between DST status and the various clinical scales used. At the end of treatment, suppressors (DST−) had significantly improved clinical ratings compared to nonsuppressors (DST+), and were mostly found among those treated with NT (71%) as compared to MOC (41%) or PBO (33%) (p < .03). On the other hand, baseline DST measures influenced treatment outcome; DST+ patients had a greater number of treatment responders to NT (48%) than MOC (19%) or PBO (20%) (p < .07). For DST− patients, the situation was reversed: NT, 7%; MOC, 31%. Postdexamethasone cortisol levels were lower in MOC responders (p < .07). An interaction was found between DST and drug-specific response. The DST may be a useful adjunct for predicting and evaluating the outcome of antidepressant therapy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alevizos B
        • Hatzimanolis J
        • Markianos M
        • Stefanis CN
        Clinical, endocrine and neurochemical effects of moclobemide in depressed patients.
        Acta Psychiatr Scand. 1993; 87: 285-290
        • The APA Task Force on Laboratory Tests in Psychiatry
        The dexamethasone suppression test: An overview of its current status in psychiatry.
        Am J Psychiatry. 1987; 144: 1253-1262
        • Arana GW
        • Workman RJ
        • Baldessarini RJ
        Association between low plasma levels of dexamethasone and elevated levels of cortisol in psychiatric patients given dexamethasone.
        Am J Psychiatry. 1984; 141: 1619-1620
        • Axelson DA
        • Doraiswamy PM
        • McDonald WM
        • Boyko OB
        • Tupler LA
        • Patterson LJ
        • et al.
        Hypercortisolemia and hippocampal changes in depression.
        Psychiatry Res. 1993; 47: 163-173
        • Barden N
        Antidepressant regulation of glucocorticoid receptor gene expression.
        Clin Neuropharmacol. 1992; 15: 586A-587A
        • Carroll BJ
        • Curtis GC
        • Mendels J
        Neuroendocrine regulation in depression: II. Discrimination of depressed from nondepressed patients.
        Arch Gen Psychiatry. 1976; 33: 1051-1058
        • Carroll BJ
        Clinical application of neuroendocrine research in depression.
        in: van Praag MH Lader MH Rafaelsen OJ Sachar EJ Handbook of Biological Psychiatry, Part III. Brain Mechanisms and Abnormal Behavior—Genetics and Neuroendocrinology. Marcel Dekker, New York1980: 179-193
        • Carroll BJ
        • Schroeder K
        • Mukhopadhyay S
        • Greden JF
        • Feinberg M
        • Ritchie J
        • et al.
        Plasma dexamethasone concentrations and cortisol suppression response in patients with endogenous depression.
        J Clin Endocrinol Metab. 1980; 51: 433-437
        • Carroll BJ
        • Feinberg M
        • Greden JF
        • Tarika J
        • Albala AA
        • Haskett RF
        • et al.
        A specific laboratory test for the diagnosis of melancholia: Standardization, validation, and clinical utility.
        Arch Gen Psychiatry. 1981; 38: 15-22
        • Carson SW
        • Halbreich U
        • Yeh CM
        • Asnis G
        • Goldstein S
        Cortisol suppression per nanogram per milliliter of plasma dexamethasone in depressive and normal subjects.
        Biol Psychiatry. 1988; 24: 569-577
        • Coryell W
        • Zimmerman M
        HPA-axis abnormalities in psychiatrically well controls.
        Psychiatry Res. 1987; 20: 265-273
        • Evans DL
        • Nemeroff CB
        The clinical use of the dexamethasone suppression test in DSM-III affective disorders: Correlation with the severe depressive subtypes of melancholia and psychosis.
        J Psychiatric Res. 1987; 21: 185-194
        • Feinberg M
        • Carroll BJ
        Biological “markers” for endogenous depression: Effects of age, severity of illness, weight loss and polarity.
        Arch Gen Psychiatry. 1984; 41: 1080-1085
        • Gastpar M
        • Gilsdorf U
        • Abou-Saleh MT
        • Ngo-Khac T
        Clinical correlates of response to DST.
        J Affect Disord. 1992; 26: 17-24
        • Guthrie SK
        • Vartanian L
        • Grunhaus L
        • Hariharan M
        • Pande A
        • Haskett RF
        A longitudinal evaluation of dexamethasone and cortisol plasma concentrations in the dexamethasone suppression test before and during treatment with antidepressant drugs.
        Acta Psychiatr Scand. 1990; 82: 427-432
        • Holsboer F
        • Haack D
        • Gerken A
        • Vecoei P
        Plasma dexamethasone concentrations and different suppression response of cortisol and corticosterone in depressives and controls.
        Biol Psychiatry. 1984; 19: 281-291
        • Hunt GE
        • Johnson GFS
        • Caterson ID
        The effect of age on cortisol and plasma dexamethasone concentrations in depressed patients and controls.
        J Affect Disord. 1989; 17: 21-32
        • Johnson GF
        • Hunt G
        • Kerr K
        • Caterson I
        The plasma dexamethasone “window” and the dexamethasone suppression test in depression.
        Biol Psychiatry. 1987; 22: 1033-1035
        • Kream J
        • Mulay S
        • Fukushima DK
        • Solomon S
        Determination of plasma dexamethasone in the mother and the newborn after administration of the hormone in a clinical trial.
        J Clin Endocrinol Metab. 1983; 56: 127-133
        • Maes M
        • Vandewoude M
        • Schotte C
        • Maes L
        • Martin M
        • Blockx P
        A revised interpretation of postdexamethasone ACTH and cortisol findings in unipolar depressed females.
        Psychiatry Res. 1990; 34: 107-126
        • Maes M
        • Minner B
        • Suy E
        Prediction of the DST results in depression by means of free urinary cortisol, availability of dexamethasone, age and diagnostic classification.
        Biol Psychiatry. 1990; 28: 349-357
        • Maguire KP
        • Schweitzer NB
        • Bridge S
        • Tiller JWG
        The dexamethasone suppression test: Importance of dexamethasone concentrations.
        Biol Psychiatry. 1987; 22: 957-967
        • Nair NPV
        • Amin M
        • Holm P
        • Katona C
        • Kiltgaard N
        • Ng Ying Kin NMK
        • et al.
        Moclobemide and nortriptyline in elderly depressed patients.
        J Affect Disord. 1995; 33: 1-9
        • O'Sullivan BT
        • Hunt GE
        • Johnson GF
        • Caterson ID
        The plasma dexamethasone window: Evidence supporting its usefulness to validate dexamethasone suppression test results.
        Biol Psychiatry. 1989; 25: 739-754
        • Poland RE
        • Rubin RT
        • Lane LA
        • Hart PJ
        • Lesser IM
        Serum dexamethasone concentration and hypothalamic-pituitary-adrenal cortical activity as determinants of the dexamethasone suppression test response.
        Arch Gen Psychiatry. 1987; 44: 790-795
        • Poland RE
        • Rubin RT
        • Lesser IM
        Serum dexamethasone concentrations in endogenous depressives before, during and after treatment: Preliminary observations.
        Biol Psychiatry. 1988; 23: 705-710
        • Ravindran AV
        • Bialik RJ
        • Lapierre YD
        Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: I. Platelet monoamine oxidase and the dexamethasone suppression test.
        J Affect Disord. 1994; 31: 111-117
        • Ribeiro SC
        • Tandon R
        • Grunhaus L
        • Greden JF
        The DST as a predictor of outcome in depression: A meta-analysis.
        Am J Psychiatry. 1993; 150: 1618-1629
        • Ritchie JC
        • Belkin BM
        • Krishnan RR
        • Nemeroff CB
        • Carroll BJ
        Plasma dexamethasone concentrations and the dexamethasone suppression test.
        Biol Psychiatry. 1990; 27: 159-173
        • Rubin RT
        • Poland RE
        • Blodgett ALN
        • Winston RA
        • Forster B
        • Carroll BJ
        Cortisol dynamics and dexamethasone pharmacokinetics in primary ED: Preliminary findings.
        in: Brambilla F Racagni G deweid D Progress in Psychoneuroendocrinology. Elsevier/North Holland, New York1980: 223-234
        • Sachar EJ
        • Puig-Antich J
        • Ryan ND
        • Asnis GM
        • Rabinovich H
        • Davies M
        • et al.
        Three tests of cortisol secretion in adult endogenous depressives.
        Acta Psychiatr Scand. 1985; 71: 1-8
        • Seckl JR
        • Fink G
        Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo.
        Neuroendocrinology. 1992; 55: 621-626
        • Stokes PE
        • Stoll PM
        • Koslow SH
        • Maas JW
        • Davis JM
        • Swann AC
        • et al.
        Pretreatment DST and hypothalamicpituitary-adrenocortical function in depressed patients and comparison groups.
        Arch Gen Psychiatry. 1984; 41: 257-267
        • Traskman L
        • Tybring G
        • Asberg M
        • Bertilsson L
        • Lautto O
        • Schalling D
        Cortisol in the CSF of depressed and suicidal patients.
        Arch Gen Psychiatry. 1980; 37: 761-767
        • Whiteford HA
        • Peabody CA
        • Csernansky JG
        • Warner MD
        • Berger PA
        Elevated baseline and postdexamethasone cortisol levels: A reflexion of severity of endogenicity?.
        J Affect Disord. 1987; 12: 199-202
        • Young RC
        • Alexopoulos GS
        • Manley MW
        • Shamoian CA
        • Dhar AK
        • Kutt H
        Treatment outcome in elderly depressives: Plasma nortriptyline concentration and pretreatment dexamethasone suppression test.
        in: Usdin E Asberg M Bertilsson L Sjoquist F Frontiers in Biochemical and Pharmacological Research in Depression. Raven Press, Amsterdam1984: 207-211